We are empowering nucleic acid therapeutics to go the distance.

Our ambition is to unlock the potential of nucleic acid therapeutics by leveraging the drug delivery capabilities of our innovative peptide technology.

Learn more about PepGen’s peptide platform

Our focus is on applying our peptide technology across a wide range of indications through independent and partnered development pathways.

Learn more about our therapeutic targets

Careers at PepGen

We’re looking for passionate, innovative individuals who can help us to deliver our technology to the people who need it most, and we’ve fostered a unique working culture to support this mission.

Learn more about working at PepGen

Latest Updates

Recent publication honoured by the OTS

A recent publication utilising the precursor technology that underpins PepGen’s platform has been awarded ‘Paper of the Month‘ by the Board of Directors and the Scientific Advisory Council of the Oligonucleotide Therapeutics Society (OTS). In addition, this publication is currently under consideration for the…

PepGen attends BioTrinity in London

PepGen attended the BioTrinity conference from the 29th of April to the 1st of May 2019. The company was represented by Damian Marron (Chairman of the Board), Dr Caroline Godfrey (CEO) and Dr Sonia Bracegirdle (CBO) at this event. Alongside meetings with potential investors and partners,…

PepGen’s £1.6M grant from Innovate UK has commenced

On the 1st of February 2019, PepGen’s £1.6M Innovate UK grant officially commenced. The company will initially focus on platform validation studies in small and large in vivo models, with project management and intellectual property workpackages running parallel to this experimental work.